On Friday, Celgene Corp, the giant drug maker, posted results of the late-stage clinical trial of its popular blood-cancer medicine, Revlimid, which not only showed strong effectiveness of the treatment, but also came out much earlier than expected, leading the pharma firm to stop the trials.

The initial results came out much earlier than anyone had expected, and have managed to provide further proof that Revlimid is very beneficial for patients suffering from multiple-myeloma, beyond its current usage.

Phase III of the trial, which was carried out by the National Cancer Institute, tested the drug as a "follow-up therapy for multiple-myeloma patients who had a stem-cell transplant", and the drug managed to meet the primary end-point of the trial much sooner by displaying that patients on the medicine had reduced their risk of the disease's progression by 58%.

"We believe that the early stoppage implies a highly robust treatment effect in favor of Revlimid", experts noted.

On the back of the drug's success, Celgene shares surged by 10.3% to $55.83 in the most recent trading session.